Gilead Sciences, the maker of hepatitis C virus (HCV) treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), made $32.6 billion in 2015, according to a press release from the pharmaceutical company detailing its fourth-quarter financial results. That represents a revenue increase of more than 30 percent from 2014.

Just in the fourth quarter of 2015, Gilead made nearly $8.5 billion, compared with $7.3 billion in the fourth quarter of 2014. Sales of its HIV and hep C treatments accounted for $7.9 billion of its 2015 annual revenues.

Sales of Gilead’s HCV drugs in the United States actually went down last year compared with 2014. However, the launch of its new HCV drugs in Japan and in Europe offset the U.S. decline.

Additional updates from Gilead include the recent approval of Genvoya, a new HIV treatment, by the U.S. Food and Drug Administration; the FDA’s approval of Harvoni for people with genotypes 4, 5 and 6 of HCV; and the submission to the FDA of a New Drug Application for sofosbuvir plus velpatasvir, an investigational once-daily hep C combo for all genotypes.